ADMA Biologics in Q1 2026: Flat Revenue, ButASCENIV Moves the Needle as Guidance Gets a Reboot

Overview: A Quarter of Stability Amid Dynamic Markets

ADMA Biologics, Inc. reported first-quarter 2026 results that showed a revenue line essentially unchanged from a year earlier, highlighted by divergent performance within its product portfolio. Total revenue for the quarter came in at $114.5 million, flat year over year. The company framed the lines differently: ASCENIV revenue rose 28% versus the prior year, while BIVIGAM revenue declined 54% in the same period. Management emphasized that the upswing in ASCENIV demand coexists with ongoing pricing and distribution dynamics in the plasma-derived therapy (PDT) and immunoglobulin (IG) markets.

From a profitability perspective, ADMA reported 1Q 2026 Adjusted Net Income of $40.7 million, up about 22% year over year, and Adjusted EBITDA of $59.7 million, up roughly 24%. Cash flow generation remains a bright spot, with operating cash flow of about $58 million. In short, the quarter looked like a steadier cadence on the top line, with margin and cash metrics signaling resilience in a challenging market backdrop.

What Mattered in the Dynamics: Demand, Dislocation, and the Mix

The press release underscores a familiar tension: ASPs and pricing discipline in the U.S. PDT/IG landscape are shaping near-term topline pressures, particularly around BIVIGAM, while ASCENIV is showing durable growth. The company attributes ASCENIV’s strength to record utilization, expanding prescriber breadth, and patient adherence—factors that could support continued revenue growth even if the broader PDT/IG market softens.

Executive commentary notes that the first-quarter results likely reflect a trough revenue baseline rather than a fundamental turn in demand weakness. In other words, ADMA is cautious about the near-term market dislocations but sees signal in ASCENIV’s demand trajectory and in the ongoing performance of its pipeline, including SG-001, which management describes as a capital-efficient opportunity with a potentially meaningful addressable market if approved.

Guidance and Outlook: A Reset, Not a Repose

ADMA updated its financial outlook for 2026, while also withdrawing its long-term guidance. The company now projects: FY 2026 total revenue in a range of $530 million to $560 million, reflecting a modest growth profile against a flat-Q1 base. Adjusted Net Income is expected to be between $170 million and $200 million, and Adjusted EBITDA between $265 million and $300 million. The decision to withdraw long-term guidance signals heightened uncertainty about the dynamic PDT/IG market and the variable forces shaping price and demand in that space.

The absence of explicit per-share figures in the release means traders and EPS enthusiasts will likely translate adjusted income into a rough EPS proxy on their own, creating the usual tension between EPS consensus expectations and what management presents as quarterly and annual performance. In the meantime, the company’s cash-generation profile provides a cushion for near-term volatility, a feature investors do not discount lightly when the burn rate for pipeline work and manufacturing remains in the mix.

Statements That Stand Out

Adam Grossman, President and CEO, framed the quarter with a mix of caution and optimism: while the market for PDT and IG has seen competitive dynamics widen distribution and ordering patterns, the fundamentals for ASCENIV remained solid and the ramp in demand persisted. He described the first-quarter performance as potentially representing a trough in revenue, before signaling confidence in near-term growth through expanding gross margins and better cash generation. He also pointed to SG-001 as a potential lever if approved, offering a path to a larger, more capital-efficient commercial opportunity.

Implications for ADMA and Sector Peers

For ADMA, the Q1 print reinforces a theme that will likely persist: core cash generation and product-level resilience can coexist with a volatile external environment. The ASCENIV-led growth story remains a differentiator in a market where BIVIGAM’s performance has been challenged. The decision to withdraw long-term guidance, paired with a precise 2026 revenue and profitability range, indicates a shift toward managing for near-term clarity amid industry-wide uncertainty.

From a sector perspective, ADMA’s results underscore a broader narrative: single-product dependence is risky in a market where regulatory dynamics, plasma product pricing, and distributor behavior can swing quarterly results. If ASCENIV can sustain demand momentum, peers with similar models might observe a partial halo effect on confidence and pricing power. Conversely, any contraction in the PDT/IG market or a fresh round of pricing pressure could compress margins, drawing attention to operating leverage, cash flow quality, and the potential of pipeline assets like SG-001 to restore growth with capital efficiency.

Analyst Lens: A Quiet Quarter, a Loud Horizon

In the vocabulary of earnings discourse, ADMA delivered a balanced script: a flat revenue line punctuated by meaningful intra-quarter variance between ASCENIV and BIVIGAM, and a constructive outlook built on cash flow and margin discipline. The absence of a traditional “earnings surprise” in the headline numbers might disappoint speculators chasing a rapid re-rating, but the durability of ASCENIV and the prospect of SG-001 offer a plausible bridge to a higher-margin future. Analysts will likely scrutinize the 2026 revenue forecast and the mid-term path to the $300 million-plus Adjusted EBITDA target, weighing these against the practical risks of a competitive PDT/IG market and potential shifts in plasma supply and pricing dynamics.

From a trading perspective, the stock narrative may hinge on how investors interpret the guidance withdrawal: is this a prudent acknowledgment of market complexity, or a signaling of slower growth ahead? The answer may hinge on ASCENIV performance and the pace at which SG-001 commercializes, if approved. Either way, the earnings architecture remains alive with a mix of profitability, cash flow, and optionality—an outcome that, in Levine’s terms, is not a straight line but at least a line with some curvature, which is what you want when you’re betting on durable demand and a pipeline that isn’t yet priced in full.

Bottom Line

ADMA Biologics’ Q1 2026 reflects a company navigating an uneven market with a steady hand: ASCENIV is carrying growth, BIVIGAM pressurizes the mix, and the company is converting revenue into cash while revising its expectations for the year. With a revenue forecast of $530–$560 million and adjusted profitability targets intact, the story now centers on whether ASCENIV can sustain momentum and whether SG-001 can unlock a larger, more capital-efficient market opportunity. For investors watching earnings metrics, the absence of a per-share figure in the release means EPS consensus will be inferred rather than declared, and the possibility of an earnings surprise will depend on how the market prices the implied forward path to the 2026 targets. In a sector where dynamics move quickly, ADMA’s focus on cash, margins, and optionality keeps the horizon interesting rather than predictable.